BioPharma Resources

Investigational drug · Phase 3

BAT1706

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignancies.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

44

Any phase or sponsor naming "BAT1706"

First trial start

2019

Dec 19, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BAT1706", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Malignancies

Largest trials

Live from ClinicalTrials.gov: studies naming "BAT1706" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Advanced Malignancies

  • LBL-007AlcestobartPhase 38 trials

    BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer

  • GimistotugBGB-A445Phase 34 trials

    BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma

  • PelabresibDAK539, CPI-0610Phase 34 trials

    Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)

  • TQB2930Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer

  • TQB3616Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

  • BGB-15025Phase 33 trials

    BeOne Medicines (BeiGene) · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Advanced Malignancies

  • SurzebiclimabBGB-A425Phase 33 trials

    BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion

  • CMP 001VidutolimodPhase 32 trials

    Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.